From the human brain to the battlefield: MSX Pre-IPO Phase III introduces Neuralink and Anduril, betting on the next frontier of AI
- MSX Maitong will open subscriptions for its Phase 3 Pre-IPO project on August 31, 2026.
- Phase 3 targets include Neuralink and Anduril, representing a shift of AI into the physical world.
- Neuralink focuses on developing brain-computer interface technology, while Anduril operates in defense technology.
- The first two phases of MSX Pre-IPO have successfully validated their investment model through public listings and buybacks.
MSX Maitong is set to launch its Phase 3 Pre-IPO project on August 31, 2026, focusing on high-growth technology companies. This phase will feature Neuralink and Anduril as key investment targets, indicating a significant shift in AI applications from digital to physical realms.
Neuralink, founded by Elon Musk, aims to develop advanced brain-computer interface systems, which include implantable devices and neural signal decoding technologies. This positions Neuralink at the forefront of cognitive technology development.
Anduril, on the other hand, operates in the defense sector, showcasing the diverse applications of AI in real-world scenarios. The successful validation of previous Pre-IPO phases through public listings and buybacks has set a strong precedent for this upcoming phase, attracting investor interest in these innovative companies.
从人脑到战场：MSX Pre-IPO第三阶段引入Neuralink和Anduril，押注AI的下一个前沿
MSX Maitong计划于2026年8月31日推出其第三阶段Pre-IPO项目，重点关注高增长技术公司。此阶段将以Neuralink和Anduril作为主要投资目标，表明AI应用从数字领域向物理领域的重要转变。
Neuralink由埃隆·马斯克创立，旨在开发先进的脑机接口系统，包括可植入设备和神经信号解码技术。这使得Neuralink处于认知技术发展的前沿。
而Anduril则在国防领域运营，展示了AI在现实场景中的多样化应用。之前Pre-IPO阶段通过公开上市和回购的成功验证，为即将到来的阶段奠定了坚实的基础，吸引了投资者对这些创新公司的兴趣。